- 入力文：• SBRT is widely used in oligometastatic breast cancer despite limited evidence. • SBRT delayed systemic therapeutic line change by over 1 year in our cohort. • Our study may help to identify patients most likely to benefit from SBRT. • SBRT is a well-tolerated treatment with limited toxicity. • Randomized trials are needed to assess the benefit of SBRT in terms of survival.
定位放射線治療が少数転移性乳がんの全身治療ラインの変更に与える影響
AIによる要点抽出